Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBio – FiercePharma
FiercePharma |
Inovio grabs $23M through HPV immunotherapy licensing deal with China's ApolloBio
FiercePharma China's ApolloBio increased its upfront payment to obtain Greater China rights to Inovio's HPV immunotherapy. Share Facebook Twitter LinkedIn Email Print. Inovio and China's ApolloBio have agreed to tweak their exclusive licensing deal formed about a … Inovio Amends Chinese Deal for Immunotherapy, Shares Up Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in … Inovio revamps China deal; nets $23M upfront payment |
